MedTrace Logo

A Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes

NCT02053272 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 207

Last updated 2022-12-20

No results posted yet for this study

Summary

A study to compare the change in glycaemic control in participants with Type 2 diabetes when treated with GWP42004 or placebo as add-on therapy to metformin over a period of 12 weeks. The safety and tolerability of GWP42004 compared with placebo will also be assessed.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

GWP42004

The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).

DRUG

Placebo

The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • Romania
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02053272 on ClinicalTrials.gov